RxDoctor Payments Data

Claudia Rodriguez Rivera, MD

Nephrology · Milwaukee, WINPI 1336676410

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Novartis at 53.2% of the total. 2025 is the largest year on record at $561, 6.1 times the $92 reported in 2022.

$1,156in general payments, 2019–2025

Across 51 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$614
  • Aurinia Pharma U.S., Inc.$125
  • Amgen$122
  • Travere Therapeutics, Inc.$111
  • Bayer$82
  • Vifor Pharma, Inc.$37
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$1,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,156 in reported general payments places this provider in the 70th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$201,928
Medicare patients
584
Services billed
1,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide39$113,737
JardianceEmpagliflozin52$63,558
FarxigaDapagliflozin Propanediol47$61,770
FosrenolLanthanum Carbonate12$25,907
LokelmaSodium Zirconium Cyclosilicate30$17,559
Sevelamer Carbonate66$8,848
Nifedipine ErNifedipine142$4,919
Bumetanide66$3,687
Potassium Citrate ErPotassium Citrate34$2,765
Calcitriol89$1,470
Losartan Potassium132$1,300
Cinacalcet Hcl11$1,243
Carvedilol129$1,131
Potassium Chloride33$790
Doxazosin Mesylate49$787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$13$63,55852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 173 nephrology providers in Wisconsin.

Other nephrology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →